Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
Second Genome, Inc., a leader in the development of novel medicines derived from the human microbiome, today announced the presentation of preclinical data and results from a Phase 1 study in healthy volunteers with its […]